NERx 505

Drug Profile

NERx 505

Alternative Names: NERx-505

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator NERx Biosciences
  • Class Small molecules
  • Mechanism of Action DNA repair inhibitors; DNA-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 Sep 2016 Preclinical trials in Cancer in USA before September 2016 (NERx Bioscience pipeline, September 2016)
  • 27 Sep 2016 NERx Biosciences receives SBIR grant from National Cancer Institute for NERx 505 development in Cancer before September 2016 (NERx pipeline, September 2016)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top